68644-48-4

Usage

Chemical structure

Contains a pyrrolidine ring and an acetamide group, a diethylaminoethyl and a phenyl group.

Common uses

Used as a drug in medical and pharmaceutical applications.

Potential uses

May be used as a central nervous system depressant and a local anesthetic.

Other pharmacological properties

May have analgesic and anticonvulsant effects, making it useful in the treatment of various medical conditions.

Research and chemical synthesis potential

May have potential uses in research and chemical synthesis due to its unique structure and properties.

Upstream product

• 70291-40-6 2-oxo-4-phenyl-1-pyrrolidineacetic acid, ethyl ester 
• 100-36-7 N,N-diethylethylenediamine 
• 68497-63-2 methyl-2-oxo-4-phenylpyrrolidine-1-acetate 
• 1198-97-6 4-phenylpyrrolidin-2-one 

Relevant academic research and scientific papers

Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl]-2-oxo-1-pyrrolidineacetamides, including pramiracetam

A series of N-[(dialkylamino)alkyl]-2-oxo-1-pyrrolidineacetamides was synthesized. The title compounds reversed electroconvulsive shock (ECS) induced amnesia in mice when administered subsequent to the ECS treatment and were inactive in a general observational test for central nervous system (CNS) activity. Active compounds exhibited an inverted U-shaped dose-response curve. Among the compounds with the broadest dose-response curve, as well as the most potent, were those with the N-[2-[bis(1-methylethyl)amino]ethyl] or 2,6-dimethylpiperidinoethyl residues as amide substituent. The N-(dialkylamino) substituent markedly enhances amnesia-reversal activity, with ethylene providing the optimal chain length. N-[2-[Bis(1-methylethyl)amino]ethyl]-2-oxo-1-pyrrolidineacetamide N(-dialkylamino) substituent was selected for preclinical toxicological evaluation, assigned the investigational number CI-879 and the U.S. adopted name (USAN) pramiracetam. Pramiracetam demonstrated a wide margin of safety in animals and was tolerated in normal human volunteers. It has shown encouraging activity in an open label trial in patients with primary degenerative dementia (PDD or senile dementia of the Alzheimer's type).

N-(Substituted-aminoalkyl)-2-oxo-1-pyrrolidineacetamides

N-(substituted-aminoalkyl)-2-oxo-1-pyrrolidineacetamides which are useful as pharmacological agents, especially cognition activators, are disclosed. They can be produced by reacting a 2-oxo-1-pyrrolidineacetate ester with an appropriate amine.